Literature DB >> 2752773

Plasma catecholamines and resuscitation from prolonged cardiac arrest.

K B Kern1, M A Elchisak, A B Sanders, S F Badylak, W A Tacker, G A Ewy.   

Abstract

Plasma catecholamine levels rise markedly with cardiac arrest and attempted resuscitation. We examined whether epinephrine (EPI) or norepinephrine (NE) plasma concentrations could predict resuscitation outcome. In nine mongrel dogs, EPI and NE levels were drawn before cardiac arrest and after 8 and 14 min of cardiac arrest and CPR. Intravenous EPI (1 mg) was given 1 min before the last plasma level was drawn. Catecholamines were quantitated by high-performance liquid chromatography with triple-electrode coulometric electrochemical detection. Plasma catecholamines increased significantly with cardiac arrest, EPI levels increased from a control level of 15.9 +/- 3.0 to 396.0 +/- 63.3 pmol/ml after 8 min of cardiac arrest (p less than .05), and NE levels similarly increased from 4.4 +/- 1.7 to 66.5 +/- 12.0 pmol/ml (p less than .01). Neither the absolute catecholamine plasma concentration nor the response to cardiac arrest of the endogenous catecholamine concentrations could predict outcome, but catecholamine responses to exogenous EPI did correlate with outcome. Animals which were subsequently resuscitated had a greater increase in the plasma EPI concentrations after exogenous EPI than animals that were not resuscitated, a 53-fold vs. a 23-fold increase (p less than .05). Successfully resuscitated animals also had increased NE levels after exogenous EPI, while unsuccessfully resuscitated animals had either no change or a decrease (p less than .02). Successfully resuscitated animals had an increase in coronary perfusion pressure (p less than .01) in response to exogenous EPI, in contrast to those that were not resuscitated. This suggests that the exogenous administration of EPI during prolonged CPR is beneficial despite markedly elevated endogenous catecholamine levels.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2752773     DOI: 10.1097/00003246-198908000-00013

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  8 in total

Review 1.  The evaluation and management of electrical storm.

Authors:  Michael Eifling; Mehdi Razavi; Ali Massumi
Journal:  Tex Heart Inst J       Date:  2011

Review 2.  Pathophysiology and pathogenesis of post-resuscitation myocardial stunning.

Authors:  Athanasios Chalkias; Theodoros Xanthos
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

3.  Use of catecholamines in CPR.

Authors:  J L Vincent
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

4.  In vivo opening of the mitochondrial permeability transition pore in a rat model of ventricular fibrillation and closed-chest resuscitation.

Authors:  Iyad M Ayoub; Jeejabai Radhakrishnan; Raúl J Gazmuri
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

5.  Association of diastolic blood pressure with survival during paediatric cardiopulmonary resuscitation.

Authors:  Caitlin E O'Brien; Polan T Santos; Michael Reyes; Shawn Adams; C Danielle Hopkins; Ewa Kulikowicz; Jennifer L Hamrick; Justin T Hamrick; Jennifer K Lee; Sapna R Kudchadkar; Elizabeth A Hunt; Raymond C Koehler; Donald H Shaffner
Journal:  Resuscitation       Date:  2019-08-04       Impact factor: 5.262

Review 6.  Adrenaline, cardiac arrest, and evidence based medicine.

Authors:  T H Rainer; C E Robertson
Journal:  J Accid Emerg Med       Date:  1996-07

7.  Post-cardiac arrest syndrome: Mechanisms and evaluation of adrenal insufficiency.

Authors:  Athanasios Chalkias; Theodoros Xanthos
Journal:  World J Crit Care Med       Date:  2012-02-04

8.  Activation of Neuropeptide Y2 Receptor Can Inhibit Global Cerebral Ischemia-Induced Brain Injury.

Authors:  Reggie Hui-Chao Lee; Celeste Yin-Chieh Wu; Cristiane T Citadin; Alexandre Couto E Silva; Harlee E Possoit; Garrett A Clemons; Christina H Acosta; Victoria A de la Llama; Jake T Neumann; Hung Wen Lin
Journal:  Neuromolecular Med       Date:  2021-05-21       Impact factor: 4.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.